

A Monthly e Magazine  
ISSN:2583-2212

August, 2023; 3(08), 2070-2076

Popular Article

# Antimicrobial Peptides: A Promising Therapeutic Approach to Tackle Antimicrobial Resistance

Subhasree Das<sup>1\*</sup>, Sukhen Samanta<sup>2</sup>

<sup>1\*</sup>Research Scholar, West Bengal University of Animal and Fishery Sciences, Department of Veterinary Biochemistry, 37 and 68, Khudiram Bose Sarani, Belgachia, Kolkata 700037, India.

<sup>2</sup>Junior Research Fellow at Eastern Regional Station, ICAR-Indian Veterinary Research Institute (ICAR-IVRI), Kolkata, West Bengal 700037, India.

<https://doi.org/10.5281/zenodo.8274157>

## Introduction

Antimicrobial peptides (AMPs) have emerged as an attainable therapeutic approach to combat AMR (antimicrobial resistance) and they have the potential to completely alter the infection control field. AMR, which is fuelled by antibiotic misuse and overuse, creates a worldwide health concern by making conventional treatment choices ineffective against a widening range of diseases. In such situation, AMPs represent a glimmer of hope.

Numerous species produce short amino acids called AMPs as a part of their regular immune response. These peptides exhibit significant antimicrobial efficacy against various pathogens, including multidrug resistant pathogens as well as bacteria, viruses and fungi. Their mode of action diverges from conventional antibiotics, as they impede with micron membranes, inhibit intracellular processes, and control the immune response of hosts. This multifaceted behaviour makes pathogens quite difficult to develop resistance to AMP. One of the most attractive aspects of AMP is their wide spectrum activity, suggesting that it can combat a number of infections using a single agent. In addition, research has shown that some AMPs have immune modulating properties and improve the ability of the immune system to detect and eliminate pathogens that invade. Despite its enormous potential, contests such as high production costs, stability concerns and regulatory obstacles have limited the medical translation of AMPs. Nevertheless, awareness in AMPs as a workable medicinal approach has been rekindled by recent developments in peptide engineering, bioinformatics, and formulation technologies. Synthetic peptides with increased stability, increased selectivity, and decreased toxicity are currently being created by researchers. Ingenious delivery methods are also being investigated to address issues with administration and bioavailability.

The creation of fresh tactics to battle AMR is crucial as we stand at the threshold of a post-

antibiotic world. Antimicrobial peptides show significant promise as a game-changing strategy to tackle this global health catastrophe because of their distinct modes of action and capacity to circumvent resistance. Continued study into their manufacture, clinical effectiveness, and optimisation may usher in a new era of infection control in which AMR is no longer an insurmountable obstacle. This article delves into the latest advancements in AMP research, shedding light on their mechanisms, challenges, and potential applications as a cornerstone of future antimicrobial therapies.

### Understanding Antimicrobial Peptides (AMPs)

AMPs are short sequences of amino acids existing in diverse species as a protection against microbial intruders. They demonstrate an amazing capacity for focusing on a variety of bacteria, viruses, fungi, and even certain parasites. AMPs can be categorised into a number of groups (Fig 1). AMPs function by rupturing the cell membranes of microorganisms, obstructing vital functions, and modifying the host immunological response. Contrary to traditional antibiotics, which frequently target certain bacterial components, AMPs offer a wider spectrum of activity and a lesser risk of developing resistance. This makes them a capable therapeutic approach in combating antimicrobial resistance. Researchers are investigating AMPs as potential therapies for illnesses that have developed a resistance to conventional antibiotics. Although there are still issues with maximising their effectiveness, stability, and manufacture, AMPs have a lot of potential to advance the treatment of infectious diseases and address the mounting problem of antimicrobial resistance.




Figure No. 1: A brief description about the AMP classified categories.

### Mechanisms of Action of AMPs

Antimicrobial peptides (AMPs) provide a possible therapeutic route to treat antimicrobial resistance. Numerous species manufacture these tiny compounds as a kind of defence against



infections. AMPs can target a variety of bacteria due to their varied modes of action. By entering the lipid bilayer, they damage microbial membranes, causing permeabilization of the membrane and cell death. Additionally, AMPs can hinder the survivability of pathogens by interfering with intracellular activities including protein and nucleic acid production. Their rapid and nonspecific mode of action reduces the likelihood of resistance development. Furthermore, AMPs have immunomodulatory properties, which improve the host's immunological response. AMPs have enormous potential as an alternative treatment strategy to standard antibiotics by harnessing these complex processes, contributing in the combat against antimicrobial resistance while providing a broad and adaptive approach to treating various illnesses (Fig 2).




Figure No. 2: Different modes of action of AMPs (Kumar *et al.*, 2018).

Table No. 1: The table below summarizes the modes of action of AMPs

Action	Mechanism	Example
Disruption of Cell Membrane	AMPs insert into microbial cell membranes, forming pores or disrupting lipid bilayers, leading to leakage of ions and vital molecules, ultimately causing cell death.	Magainin-2: Forms pores in bacterial membranes.
Direct Microbial Killing	AMPs can directly interact with microbial components, like DNA, RNA, and proteins, disrupting essential processes and causing microbial death.	LL-37: Inhibits replication by binding to DNA.
Immunomodulation	AMPs can stimulate the immune response by recruiting immune cells, enhancing phagocytosis, and promoting inflammation, which aids in pathogen clearance.	Defensins: Attract immune cells to the infection site.
Biofilm Disruption	AMPs can penetrate and disrupt biofilms, which are protective communities of microorganisms, making them more susceptible to immune attacks and antibiotics.	Bac7: Disrupts biofilm matrix and kills bacteria.



Synergy with Antibiotics	AMPs can enhance the effectiveness of traditional antibiotics by disrupting microbial membranes, making bacteria more permeable to antibiotics and reducing resistance.	Polymyxin B: Enhances the action of beta-lactams.
Low Resistance Development	AMPs target multiple microbial components, making it difficult for bacteria to develop resistance through single mutations, thus reducing the emergence of resistant strains.	Daptomycin: Targets bacterial cell membrane and DNA.

### Challenges of Conventional Antibiotics and Rising Antimicrobial Resistance

Antimicrobial resistance (AMR) has emerged as a consequence of conventional antibiotics' excessive and improper usage, despite their crucial role in the management of bacterial illnesses. This terrible problem reduces the efficacy of antibiotics and poses a serious risk to the general public's health. AMR development is accelerated by an over-reliance on a small number of antibiotic classes, prompting the investigation of complementary medicines. The potential efficacy of AMPs as a therapy method has garnered interest. These naturally occurring small proteins can break bacterial membranes and have broad-spectrum antibacterial activities, which reduces the likelihood of resistance forming. Nonetheless, the experimental translation of AMPs encounters obstacles like stability, scalability, and cost. Effective strategies to address these challenges are imperative to harness AMPs' potential in combating AMR and offering a diversified arsenal against bacterial infections.

### Potential of AMPs as a Therapeutic Approach

AMPs are promising treatments for the global challenges of AMR. These organic short peptides provide broad-spectrum antimicrobial activity against a range of pathogens, including as bacteria, viruses, and fungus. Their unique mode of action, often involving disruption of microbial membranes or interference with intracellular processes, reduces the likelihood of resistance development. AMPs also retain immunomodulatory belongings that can enhance the host's innate immune response. Furthermore, their potential for synergy with existing antibiotics and minimal proclivity for resistance make them an appealing possibility for therapeutic development. However, challenges remain in optimizing their stability, bioavailability, and cost-effectiveness for clinical use. As research advances, harnessing the potential of AMPs holds promise for combating AMR and diversifying our therapeutic arsenal against infectious diseases.

**Table No. 2: Demonstrating a few instances of AMPs and their potential as a therapeutic approach against antibiotic-resistant microorganisms.**

AMP Name	Source	Mechanism of Action	Target Organisms	Potential as Therapeutic Approach
Defensins	Various organisms	Membrane disruption, immune modulation	Bacteria, fungi, viruses	Different classes of defensins are found in plants, animals, and insects. Some show



				promise against resistant pathogens.
Nisin	Lactic acid bacteria	Interferes with cell wall synthesis	Gram-positive bacteria	Effective counter to Gram-positive bacteria, including some antibiotic-resistant strains.
Bacitracin	Bacterial origin	Prevents cell wall synthesis	Gram-positive bacteria	Used in topical applications; active against Gram-positive bacteria, but resistance can develop.
Plectasin	Fungal origin	Constrains cell wall synthesis	Gram-positive bacteria	Shows potential against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections.
Polymyxins	Bacterial origin	Disrupts cell membrane	Gram-negative bacteria	Reserved for multidrug-resistant Gram-negative infections due to potential toxicity.
Daptomycin	Bacterial lipopeptide	Disrupts cell membranes	Gram-positive bacteria	Approved for use against certain drug-resistant Gram-positive infections.
Temporins	Frog skin peptide	Membrane disruption	Bacteria	Exhibit antimicrobial action against bacteria, including some antibiotic-resistant strains.
LL-37	Human cathelicidin	Membrane disruption	Bacteria, fungi	Exhibits broad-spectrum antimicrobial activity and immunomodulatory effects. Can enhance host immune responses.
Magainins	Frog skin peptide	Membrane disruption	Bacteria	Known for their membrane-disrupting activity, potentially useful against drug-resistant bacteria.
MSI-78	Synthetic peptide	Membrane disruption	Bacteria, fungi	Exhibits antimicrobial activity against both bacteria and fungi, including resistant strains.

### Challenges and Limitations of AMPs as Therapeutics

AMPs are a promising strategy to treating AMR, but they are not without challenges and limitations. For starters, there in vivo vulnerability to enzymatic degradation might limit their stability and efficiency. Furthermore, the possibility of off-target interactions with host cells raises toxicity concerns. The inaccessibility of AMPs for general application is hampered by their expensive production and purifying costs. Moreover, variability in effectiveness against different pathogens and



strains necessitates careful selection and optimization. Development of resistance by microbes against AMPs remains a concern, although less likely than conventional antibiotics. Furthermore, limited pharmacokinetic properties and rapid clearance from the body can impede their therapeutic window. To harness the potential of AMPs against AMR, these challenges must be overcome through innovative formulation strategies, targeted delivery systems, and comprehensive clinical evaluations.

**Table No. 3: Listing the challenges and limitations of AMPs as therapeutic agents to tackle AMR.**

Sl No.	Challenges and Limitations	Description
1.	Selectivity	Some AMPs can exhibit non-specific activity against host cells, leading to potential toxicity and unintended side effects.
2.	Stability	AMPs can be susceptible to degradation by enzymes and proteases, reducing their effectiveness and stability in complex environments.
3.	Resistance Development	Bacteria can develop resistance mechanisms against AMPs, similar to antibiotic resistance, through mutations and efflux pumps.
4.	High Cost of Production	It might be expensive to produce and purify AMPs on a large scale, limiting their feasibility for widespread clinical use.
5.	Limited Spectrum	Many AMPs have a constricted range of activity, being effective against certain pathogens but not all types of bacteria or fungi.
6.	Synergy with Antibiotics	Combining AMPs with traditional antibiotics could enhance efficacy, but interactions may vary and need careful optimization.
7.	Immunogenicity	Some AMPs might trigger immune responses, potentially leading to allergic reactions or reduced efficacy upon repeated use.
8.	Formulation Challenges	Developing stable and effective delivery systems for AMPs to target specific infection sites while preserving activity is complex.
9.	Clinical Trial Complexity	Designing and conducting clinical trials for novel AMP-based therapies require rigorous testing for safety and efficacy.
10.	Regulatory Hurdles	Regulatory approval processes for new antimicrobial agents can be stringent and time-consuming, affecting their timely availability.

### Strategies to Optimize AMPs for Clinical Use

AMPs offer a promising therapeutic avenue to combat antimicrobial resistance (AMR) due to their diverse modes of action and limited resistance development. To enhance AMPs for clinical use, several strategies can be employed. First, structural modifications can enhance stability and activity while minimizing toxicity. Rational design and high-throughput screening can aid in identifying potent AMP sequences. Formulation improvements, such as encapsulation or conjugation, can extend stability and bioavailability. Combining multiple AMPs with synergistic effects could broaden antimicrobial spectrum and hinder resistance emergence. Additionally, AMP dosing regimens should be optimized for efficacy and minimal resistance selection. Further research on pharmacokinetics and in vivo studies is essential for understanding AMP behavior in complex environments. Ultimately, a combination of these strategies will contribute to harnessing the full potential of AMPs as effective



antimicrobial agents in the battle against AMR.

### Future Prospects and Outlook

Antimicrobial peptides hold significant promise in addressing AMR. As natural defense molecules, they unveil broad-spectrum activity against various pathogens. Ongoing research aims to enhance their stability, specificity, and delivery mechanisms for effective clinical application. Combining AMPs with conventional antibiotics or designing synthetic variants could yield synergistic effects, minimizing resistance development. Additionally, personalized approaches to target specific pathogens could optimize treatment outcomes. Despite challenges in cost, scale-up, and clinical validation, AMPs represent a beacon of hope in the fight against AMR, offering a multifaceted strategy to combat evolving microbial threats.

### Conclusion

In conclusion, antimicrobial peptides represent a highly promising therapeutic strategy to effectively combat antimicrobial resistance. Their diverse mechanisms of action, potency against a widespread variety of pathogens, and potential for minimal resistance development make them an attractive option. However, to maximize their effectiveness, reduce any potential negative effects, and assure cost-effective manufacture, more research is required. As we face a critical global threat from resistant infections, harnessing the potential of antimicrobial peptides could offer a vital solution to preserve the effectiveness of our prevailing antimicrobial arsenal.

### References

- Bellotti, D., & Remelli, M. (2022). Lights and shadows on the therapeutic use of antimicrobial peptides. *Molecules*, 27(14), 4584.
- Hassan, M., Kjos, M., Nes, I. F., Diep, D. B., & Lotfipour, F. (2012). Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. *Journal of applied microbiology*, 113(4), 723-736.
- Kumar, P., Kizhakkedathu, J. N., & Straus, S. K. (2018). Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. *Biomolecules*, 8(1), 4.
- Luo, X., Chen, H., Song, Y., Qin, Z., Xu, L., He, N., Tan, Y. and Dessie, W., 2022. Advancements, challenges and future perspectives on peptide-based drugs: Focus on antimicrobial peptides. *European Journal of Pharmaceutical Sciences*, p.106363.
- Mba, I. E., & Nweze, E. I. (2022). Focus: Antimicrobial Resistance: Antimicrobial Peptides Therapy: An Emerging Alternative for Treating Drug-Resistant Bacteria. *The Yale journal of biology and medicine*, 95(4), 445.
- Patrulea, V., Borchard, G., & Jordan, O. (2020). An update on antimicrobial peptides (AMPs) and their delivery strategies for wound infections. *Pharmaceutics*, 12(9), 840.

